{"id":9288,"date":"2020-05-05T16:37:29","date_gmt":"2020-05-05T11:07:29","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9288"},"modified":"2021-07-24T12:57:54","modified_gmt":"2021-07-24T07:27:54","slug":"recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests","title":{"rendered":"Acquisition of Stemline; Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test; Newron\u2019s abandonment of STARS trial"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Florence-based\nMenarini Group has announced a USD667 million acquisition of the Stemline\nTherapeutics, an oncology-focused company.<\/strong><\/h2>\n\n\n\n<div class=\"wp-block-media-text alignwide\" style=\"grid-template-columns:24% auto\"><figure class=\"wp-block-media-text__media\"><img decoding=\"async\" width=\"184\" height=\"69\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05111204\/image.png\" alt=\"\" class=\"wp-image-9290\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p> As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. <\/p>\n<\/div><\/div>\n\n\n\n<p>The therapy had received FDA recommendation in 2018 as the first-ever approved treatment for blastic plasmacytoid dendritic cell neoplasm. After the announcement, the shares of Stemline therapeutics rose over 153%. <\/p>\n\n\n\n<p>Moreover, the\ncompany also plans to support Stemline in the launch of Elzonris, through its\nmanufacturing hubs, in Europe and other emerging markets after it gets\nrespective regulatory approvals, as the latter will continue with the trials\nand evaluation of Elzonris as a potential treatment for additional challenging\nto treat diseases and cancers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test gets a green-light from the US FDA for the diagnosis of COVID-19. <\/strong><\/h2>\n\n\n\n<div class=\"wp-block-media-text alignwide\" style=\"grid-template-columns:24% auto\"><figure class=\"wp-block-media-text__media\"><img decoding=\"async\" width=\"186\" height=\"101\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05111345\/image-1.png\" alt=\"\" class=\"wp-image-9292\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>The Elecsys Anti-SARS-CoV-2 immunoassay will help in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog\"><strong>diagnosis of COVID-19<\/strong><\/a> and is an in-vitro test that detects the antibodies in the human serum and plasma from a blood sample. The test will also help in studying the immune response against SARS-CoV-2.  <\/p>\n<\/div><\/div>\n\n\n\n<p>&nbsp;The company claims that its serology test has\na specificity greater than 99.8% and sensitivity of 100% at two weeks following\nPCR confirmation. It has the potential to identify the antibodies against\nSARS-CoV-2 with few false-positive results. The test is reliable enough to\ndetect if the individual has been exposed to the virus or has started to\ndevelop the antibodies. <\/p>\n\n\n\n<p>Elecsys\nAnti-SARS-CoV-2 immunoassay has been approved under EUA in the U.S. and Europe.\n<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Newron Pharmaceuticals announces the termination of the trial for sarizotan in Rett syndrome<\/strong> <strong>as the<\/strong> <strong>drug failed to meet the primary\/ secondary endpoints.<\/strong> <\/h2>\n\n\n\n<div class=\"wp-block-media-text alignwide\" style=\"grid-template-columns:26% auto\"><figure class=\"wp-block-media-text__media\"><img decoding=\"async\" width=\"176\" height=\"103\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05111513\/image-3.png\" alt=\"\" class=\"wp-image-9294\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p> The decision was based on the topline results of the trial \u2013 STARS \u2013 of sarizotan, which is a highly selective modulator of specific serotonin or dopamine receptors in the brain.  <\/p>\n<\/div><\/div>\n\n\n\n<p>The trial which was studying the result of sarizotan for the treatment of apnea in <a href=\"https:\/\/www.delveinsight.com\/report-store\/rett-syndrome-market?utm_source=blog\">Rett syndrome<\/a> enrolled 129 patients across the U.S., Europe, Asia and Australia. <\/p>\n\n\n\n<p>Newron now\nplans to focus on Phase III trial of its schizophrenia drug \u2013 evenamide, which\nit delayed the last summer. It also has its Xadago\/safinamide has been approved\nfor Parkinson\u2019s disease in Europe, Switzerland, the U.S., Australia, Canada,\nBrazil, Colombia, the United Arab Emirates and Japan, and now plans to look for\nand evaluate additional pipeline candidates.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. The therapy had received FDA recommendation in 2018 as the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9300,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18292,18293,639,5789,524,1519],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-9288","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-menarini","tag-newron-pharmaceuticals","tag-pharma-news","tag-recent-pharma-news","tag-roche","tag-schizophrenia","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acquisition of Stemline; Roche\u2019s antibody test; Newron\u2019s STARS trial result<\/title>\n<meta name=\"description\" content=\"Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test gets a green-light from the US FDA for the diagnosis of COVID-19 under EUA as well as in Europe.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acquisition of Stemline; Roche\u2019s antibody test; Newron\u2019s STARS trial result\" \/>\n<meta property=\"og:description\" content=\"Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test gets a green-light from the US FDA for the diagnosis of COVID-19 under EUA as well as in Europe.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-05T11:07:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05163451\/News.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acquisition of Stemline; Roche\u2019s antibody test; Newron\u2019s STARS trial result","description":"Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test gets a green-light from the US FDA for the diagnosis of COVID-19 under EUA as well as in Europe.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests","og_locale":"en_US","og_type":"article","og_title":"Acquisition of Stemline; Roche\u2019s antibody test; Newron\u2019s STARS trial result","og_description":"Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test gets a green-light from the US FDA for the diagnosis of COVID-19 under EUA as well as in Europe.","og_url":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-05-05T11:07:29+00:00","article_modified_time":"2021-07-24T07:27:54+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05163451\/News.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests","url":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests","name":"Acquisition of Stemline; Roche\u2019s antibody test; Newron\u2019s STARS trial result","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05163451\/News.jpg","datePublished":"2020-05-05T11:07:29+00:00","dateModified":"2021-07-24T07:27:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Roche\u2019s Elecsys Anti-SARS-CoV-2 antibody test gets a green-light from the US FDA for the diagnosis of COVID-19 under EUA as well as in Europe.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recentpharma-acquisitions-trials-resuts-covid-diagnosis-tests#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05163451\/News.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05163451\/News.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/05163451\/News-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Menarini<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Newron Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Menarini<\/span>","<span class=\"advgb-post-tax-term\">Newron Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 5, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 5, 2020 4:37 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9288"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9288\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9300"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9288"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9288"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}